1. FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib. (10th June 2021) Authors: Saung, May Tun; Pelosof, Lorraine; Casak, Sandra; Donoghue, Martha; Lemery, Steven; Yuan, Mengdie; Rodriguez, Lisa; Schotland, Peter; Chuk, Meredith; Davis, Gina; Goldberg, Kirsten B.; Theoret, Marc R.; Pazdur, Richard; Fashoyin-Aje, Lola Journal: Oncologist Issue: Volume 26:Number 9(2021) Page Start: 797 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs. (17th December 2019) Authors: Kim, Janice; Nair, Abhilasha; Keegan, Patricia; Beaver, Julia A.; Kluetz, Paul G.; Pazdur, Richard; Chuk, Meredith; Blumenthal, Gideon M. Journal: Oncologist Issue: Volume 25:Number 4(2020) Page Start: 348 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib. (10th June 2021) Authors: Saung, May Tun; Pelosof, Lorraine; Casak, Sandra; Donoghue, Martha; Lemery, Steven; Yuan, Mengdie; Rodriguez, Lisa; Schotland, Peter; Chuk, Meredith; Davis, Gina; Goldberg, Kirsten B.; Theoret, Marc R.; Pazdur, Richard; Fashoyin‐Aje, Lola Journal: Oncologist Issue: Volume 26:Number 9(2021) Page Start: 797 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Recommendations for Dose Selection for Adolescent Patients in Relevant Adult Oncology Clinical Trials. Issue 4 (21st November 2021) Authors: Leong, Ruby; Liu, Qi; Li, Lingjue; Liu, Jiang; Ren, Yunzhao R.; Lee, Peter; Chuk, Meredith; Reaman, Gregory; Wang, Yaning Journal: Clinical pharmacology & therapeutics Issue: Volume 111:Issue 4(2022) Page Start: 956 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗